What Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Sell
36
HRTS Quote, Financials, Valuation and Earnings
Last price:
$27.31
Seasonality move
:
1.11%
Day range:
$27.13 - $27.48
52-week range:
$25.32 - $36.03
Dividend yield:
0.53%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
4.9K
Avg. volume:
8.5K
1-year change:
-15.25%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Tema GLP-1, Obesity & Cardiometabolic ETF has -- downside to fair value with a price target of -- per share.
HRTS vs. S&P 500
-
Over the past 5 trading days, Tema GLP-1, Obesity & Cardiometabolic ETF has underperformed the S&P 500 by -6.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Tema GLP-1, Obesity & Cardiometabolic ETF does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tema GLP-1, Obesity & Cardiometabolic ETF has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Tema GLP-1, Obesity & Cardiometabolic ETF reported revenues of --.
Earnings Growth
-
Tema GLP-1, Obesity & Cardiometabolic ETF has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Tema GLP-1, Obesity & Cardiometabolic ETF reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-05-14 | 2024-05-14 | 2024-05-14 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-05-14 | 2022-05-14 | 2023-05-14 | 2024-05-14 | ||
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | -- | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | -- | -- | |
| Total Equity | -- | -- | -- | -- | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-05-14 | 2024-05-14 | 2024-05-14 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
HRTS
Sector
Market Cap
--
--
Price % of 52-Week High
75.3%
--
Dividend Yield
0.53%
--
Shareholder Yield
--
--
1-Year Price Total Return
-15.25%
--
Beta (5-Year)
--
--
Dividend yield:
0.53%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$27.98
200-day SMA
Sell
Level
$31.34
Bollinger Bands (100)
Sell
Level
28.16 - 30.4
Chaikin Money Flow
Sell
Level
-53.1K
20-day SMA
Sell
Level
$28.07
Relative Strength Index (RSI14)
Sell
Level
40.50
ADX Line
Sell
Level
26.23
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$28.70
MACD (12, 26)
Sell
Level
-0.23
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Sell
Level
-812.5K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, HRTS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HRTS average analyst price target in the past 3 months is --.
-
Where Will Tema GLP-1, Obesity & Cardiometabolic ETF Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tema GLP-1, Obesity & Cardiometabolic ETF share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Tema GLP-1, Obesity & Cardiometabolic ETF?
Analysts are divided on their view about Tema GLP-1, Obesity & Cardiometabolic ETF share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tema GLP-1, Obesity & Cardiometabolic ETF is a Sell and believe this share price will rise from its current level to --.
-
What Is Tema GLP-1, Obesity & Cardiometabolic ETF's Price Target?
The price target for Tema GLP-1, Obesity & Cardiometabolic ETF over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HRTS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tema GLP-1, Obesity & Cardiometabolic ETF is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of HRTS?
You can purchase shares of Tema GLP-1, Obesity & Cardiometabolic ETF via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tema GLP-1, Obesity & Cardiometabolic ETF shares.
-
What Is The Tema GLP-1, Obesity & Cardiometabolic ETF Share Price Today?
Tema GLP-1, Obesity & Cardiometabolic ETF was last trading at $27.31 per share. This represents the most recent stock quote for Tema GLP-1, Obesity & Cardiometabolic ETF. Yesterday, Tema GLP-1, Obesity & Cardiometabolic ETF closed at $27.13 per share.
-
How To Buy Tema GLP-1, Obesity & Cardiometabolic ETF Stock Online?
In order to purchase Tema GLP-1, Obesity & Cardiometabolic ETF stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Which Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Is Gartner a Safe Stock to Own?
Gartner (NYSE:IT) is among the world’s largest consulting, research and…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 44x
Alerts
Buy
57
RGC alert for May 14
Regencell Bioscience Holdings [RGC] is down 31.81% over the past day.
Buy
54
HALO alert for May 14
Halozyme Therapeutics [HALO] is down 24.57% over the past day.
Buy
91
COIN alert for May 14
Coinbase Global [COIN] is up 24.64% over the past day.
